# A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

> clinical trial · VERIFIED · 2026-08-14

Status: NOT_YET_RECRUITING · Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Condition: Primary Light Chain (AL) Amyloidosis

- Company: Shenzhen Fosun Kairos Biotechnology Co., Ltd.
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT07765524

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.